Prevail Therapeutics
PRVL
PRVL was delisted on the 21st of January, 2021.
67 hedge funds and large institutions have $421M invested in Prevail Therapeutics in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 5 closing their positions.
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
92% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 13
17% more capital inflows, than outflows
Capital inflows: $58.3M | Capital outflows: $50M
16% more funds holding
Funds holding: 58 → 67 (+9)
1.2% more ownership
Funds ownership: 81.42% → 82.62% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avidity Partners Management
Dallas,
Texas
|
+$15.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.61M |
| 4 |
BlackRock
New York
|
+$4.81M |
| 5 |
Morgan Stanley
New York
|
+$4.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
-$29M |
| 2 |
RA Capital Management
Boston,
Massachusetts
|
-$11.5M |
| 3 |
BVF Inc
San Francisco,
California
|
-$5.26M |
| 4 |
Omega Fund Management
Boston,
Massachusetts
|
-$1.31M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$718K |
PRVL Hedge Fund Activity: Q2 2020 in Review
67 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics (PRVL) for Q2 2020, worth a combined $421M — up 24% from $339M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PRVL positions and 5 closed out — a net gain of 9 holders — while 25 added to existing stakes and 13 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $15.8M. The largest seller was EcoR1 Capital, cutting an estimated $29M.
- 67 institutional investors held Prevail Therapeutics (PRVL) as of Q2 2020, up from 58 in Q1 2020.
- Funds reported $421M of Prevail Therapeutics stock for Q2 2020, up 24% quarter-over-quarter.
- 14 funds opened new Prevail Therapeutics positions in Q2 2020 and 5 closed out, a net change of +9 holders.
- The largest Prevail Therapeutics buyer in Q2 2020 was Avidity Partners Management, an estimated $15.8M added.
- The largest Prevail Therapeutics seller in Q2 2020 was EcoR1 Capital, an estimated $29M sold.
Based on aggregated 13F filings for Q2 2020.